{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:55:38Z","timestamp":1790009738890,"version":"4.0.1"},"reference-count":101,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T00:00:00Z","timestamp":1472428800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T00:00:00Z","timestamp":1472428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Pharm Pract"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1111\/ijpp.12302","type":"journal-article","created":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T04:32:41Z","timestamp":1472445161000},"page":"18-30","source":"Crossref","is-referenced-by-count":29,"title":["Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections"],"prefix":"10.1093","volume":"25","author":[{"given":"Derek","family":"Murrell","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences; Gatton College of Pharmacy; East Tennessee State University; Johnson City TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Bossaer","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice; Gatton College of Pharmacy; East Tennessee State University; Johnson City TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Carico","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice; Gatton College of Pharmacy; East Tennessee State University; Johnson City TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Harirforoosh","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences; Gatton College of Pharmacy; East Tennessee State University; Johnson City TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cluck","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice; Gatton College of Pharmacy; East Tennessee State University; Johnson City TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,8,29]]},"reference":[{"key":"10.1111\/ijpp.12302-BIB0001|ijpp12302-cit-0001","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1086\/652237","article-title":"The 10 by \u201820 initiative: pursuing global commitment to develop 10 new antimicrobial drugs by 2020","volume":"50","author":"Infectious Diseases Society of America","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1111\/ijpp.12302-BIB0002|ijpp12302-cit-0002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24\u00a0179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/ijpp.12302-BIB0003|ijpp12302-cit-0003","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1212292","article-title":"The index case for the fungal meningitis outbreak in the United States","volume":"367","author":"Pettit","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/ijpp.12302-BIB0004|ijpp12302-cit-0004","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1179\/1973947812Y.0000000051","article-title":"Voriconazole in clinical practice","volume":"24","author":"Mikulska","year":"2012","journal-title":"J Chemother"},{"key":"10.1111\/ijpp.12302-BIB0005|ijpp12302-cit-0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofu022","article-title":"Spinal and paraspinal fungal infections associated with contaminated methylprednisolone injections","volume":"1","author":"Moudgal","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"10.1111\/ijpp.12302-BIB0006|ijpp12302-cit-0006","unstructured":"Luke DR et\u00a0al Renal effects of intravenous voriconazole in patients with compromised renal function 2010"},{"key":"10.1111\/ijpp.12302-BIB0007|ijpp12302-cit-0007","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2334-13-14","article-title":"Evaluation of intravenous voriconazole in patients with compromised renal function","volume":"13","author":"Lilly","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1111\/ijpp.12302-BIB0008|ijpp12302-cit-0008","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12281-014-0185-y","article-title":"Update on posaconazole pharmacokinetics: comparison of old and new formulations","volume":"8","author":"Percival","year":"2014","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1111\/ijpp.12302-BIB0009|ijpp12302-cit-0009","first-page":"766","article-title":"Drug evaluation: BAL-8557-a novel broad-spectrum triazole antifungal","volume":"7","author":"Odds","year":"2006","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1111\/ijpp.12302-BIB0010|ijpp12302-cit-0010","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1517\/13543780903176407","article-title":"New generation azole antifungals in clinical investigation","volume":"18","author":"Girmenia","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/ijpp.12302-BIB0011|ijpp12302-cit-0011","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0960-894X(02)00892-2","article-title":"Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole","volume":"13","author":"Ohwada","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1111\/ijpp.12302-BIB0012|ijpp12302-cit-0012","unstructured":"US Food and Drug Administration Isavuconazonium - invasive aspergillosis and invasive mucormycosis. Advisory Committee Briefing Document 2015 www.FDA.gov\/downloads\/advisory"},{"key":"10.1111\/ijpp.12302-BIB0013|ijpp12302-cit-0013","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1128\/CMR.12.4.501","article-title":"Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance","volume":"12","author":"Ghannoum","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"10.1111\/ijpp.12302-BIB0014|ijpp12302-cit-0014","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1517\/17425255.2012.683859","article-title":"Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections","volume":"8","author":"Livermore","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1111\/ijpp.12302-BIB0015|ijpp12302-cit-0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tim.2010.02.004","article-title":"Therapy for fungal diseases: opportunities and priorities","volume":"18","author":"Denning","year":"2010","journal-title":"Trends Microbiol"},{"key":"10.1111\/ijpp.12302-BIB0016|ijpp12302-cit-0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11046-014-9772-2","article-title":"Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values","volume":"178","author":"Castanheira","year":"2014","journal-title":"Mycopathologia"},{"key":"10.1111\/ijpp.12302-BIB0017|ijpp12302-cit-0017","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1128\/AAC.01217-06","article-title":"In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates","volume":"51","author":"Seifert","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0018|ijpp12302-cit-0018","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.diagmicrobio.2015.04.008","article-title":"Isavuconazole, micafungin, and 8 comparator antifungal agents\u2019 susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values","volume":"82","author":"Pfaller","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/ijpp.12302-BIB0019|ijpp12302-cit-0019","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1128\/AAC.01512-07","article-title":"In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species","volume":"52","author":"Guinea","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0020|ijpp12302-cit-0020","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.diagmicrobio.2011.08.006","article-title":"In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing","volume":"71","author":"Rudramurthy","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/ijpp.12302-BIB0021|ijpp12302-cit-0021","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1111\/j.1439-0507.2010.01996.x","article-title":"In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs","volume":"54","author":"Shivaprakash","year":"2011","journal-title":"Mycoses"},{"key":"10.1111\/ijpp.12302-BIB0022|ijpp12302-cit-0022","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/dki399","article-title":"In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp","volume":"57","author":"Warn","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/ijpp.12302-BIB0023|ijpp12302-cit-0023","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1128\/AAC.00636-13","article-title":"Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method","volume":"57","author":"Espinel-Ingroff","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0024|ijpp12302-cit-0024","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1128\/JCM.00863-13","article-title":"In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds","volume":"51","author":"Pfaller","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1111\/ijpp.12302-BIB0025|ijpp12302-cit-0025","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/jac\/dkn076","article-title":"Activity of BAL 4815 against filamentous fungi","volume":"61","author":"Martin de la Escalera","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/ijpp.12302-BIB0026|ijpp12302-cit-0026","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/13693780802562969","article-title":"In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi","volume":"47","author":"Gonzalez","year":"2009","journal-title":"Med Mycol"},{"key":"10.1111\/ijpp.12302-BIB0027|ijpp12302-cit-0027","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1179\/joc.2009.21.3.272","article-title":"In vitro antifungal activity of isavuconazole against 345 Mucorales isolates collected at study centers in eight countries","volume":"21","author":"Verweij","year":"2009","journal-title":"J Chemother"},{"issue":"Suppl 3","key":"10.1111\/ijpp.12302-BIB0028|ijpp12302-cit-0028","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/myc.12234","article-title":"Molecular characterization and in\u00a0vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India","volume":"57","author":"Chowdhary","year":"2014","journal-title":"Mycoses"},{"key":"10.1111\/ijpp.12302-BIB0029|ijpp12302-cit-0029","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1128\/AAC.01919-15","article-title":"In vitro Activity of Isavuconazole and Comparators against Clinical Isolates of Mucorales Order","volume":"59","author":"Arendrup","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0030|ijpp12302-cit-0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01216-08","article-title":"Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans","volume":"53","author":"Thompson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0031|ijpp12302-cit-0031","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1128\/AAC.00646-08","article-title":"Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans","volume":"52","author":"Thompson","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0032|ijpp12302-cit-0032","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijantimicag.2010.06.003","article-title":"In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan","volume":"36","author":"Yamazaki","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/ijpp.12302-BIB0033|ijpp12302-cit-0033","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1128\/AAC.01141-13","article-title":"In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole","volume":"57","author":"Gregson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0034|ijpp12302-cit-0034","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1128\/AAC.04055-14","article-title":"Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method","volume":"59","author":"Espinel-Ingroff","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0035|ijpp12302-cit-0035","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1128\/AAC.01384-07","article-title":"In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba","volume":"52","author":"Illnait-Zaragozi","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0036|ijpp12302-cit-0036","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1128\/AAC.01530-08","article-title":"In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing","volume":"53","author":"Perkhofer","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0037|ijpp12302-cit-0037","unstructured":"Seyedmousavi S et\u00a0al In vitro activity of isavuconazole compared with itraconazole, voriconazole, and posaconazole in azole-resistant Aspergillus fumigatus [M-1377] 2013"},{"key":"10.1111\/ijpp.12302-BIB0038|ijpp12302-cit-0038","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1128\/AAC.03779-14","article-title":"EUCAST testing of isavuconazole susceptibility in Aspergillus: comparison of results for inoculum standardization using conidium counting versus optical density","volume":"58","author":"Arendrup","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0039|ijpp12302-cit-0039","unstructured":"Meis JF et\u00a0al In vitro activity of isavuconazole against a worldwide collection of 237 Aspergillus section Terrei isolates and compared with 7 other Aspergillus active antifungal drugs tested with EUCAST and CLSI methodology [M-332] 2012"},{"key":"10.1111\/ijpp.12302-BIB0040|ijpp12302-cit-0040","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/jdiagmicrobio.2014.03.004","article-title":"Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp","volume":"79","author":"Pfaller","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/ijpp.12302-BIB0041|ijpp12302-cit-0041","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s15010-013-0570-4","article-title":"Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern","volume":"42","author":"Taj-Aldeen","year":"2014","journal-title":"Infection"},{"key":"10.1111\/ijpp.12302-BIB0042|ijpp12302-cit-0042","doi-asserted-by":"publisher","first-page":"942","DOI":"10.3109\/13693781003690067","article-title":"Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18\u00a0years in a single institution in Madrid, Spain","volume":"48","author":"Guinea","year":"2010","journal-title":"Med Mycol"},{"key":"10.1111\/ijpp.12302-BIB0043|ijpp12302-cit-0043","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1128\/AAC.05910-11","article-title":"Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species","volume":"56","author":"Lackner","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0044|ijpp12302-cit-0044","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1128\/AAC.01111-13","article-title":"Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method","volume":"57","author":"Howard","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0045|ijpp12302-cit-0045","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1128\/jcm.01190-13","article-title":"Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii: emerging fungal pathogens with reduced azole susceptibility","volume":"51","author":"Datta","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1111\/ijpp.12302-BIB0046|ijpp12302-cit-0046","doi-asserted-by":"crossref","unstructured":"Curfs-Breuker IM et\u00a0al In vitro activity of isavuconazole (BAL4815) compared with seven other antifungal agents against 309 prospectively collected clinical candida isolates from The Netherlands 2007","DOI":"10.1016\/S0924-8579(07)71817-4"},{"key":"10.1111\/ijpp.12302-BIB0047|ijpp12302-cit-0047","unstructured":"Cuenca-Estrella A et\u00a0al BAL4815 a new antifungal agent: determination of quality control limits for susceptibility testing by methods of the european committee on antimicrobial susceptibility testing (EUCAST) 2006"},{"key":"10.1111\/ijpp.12302-BIB0048|ijpp12302-cit-0048","doi-asserted-by":"crossref","unstructured":"Heep M et\u00a0al Evaluation of isavuconazole e-test compared to broth microdilution antifungal susceptibility testing against quality control strains and clinical Candida isolates 2007","DOI":"10.1016\/S0924-8579(07)71515-7"},{"key":"10.1111\/ijpp.12302-BIB0049|ijpp12302-cit-0049","unstructured":"Ostrosky-Zeichner L et\u00a0al Comparative in\u00a0vitro activity of isavuconazole (ISA) against medically important yeasts and moulds 2009"},{"key":"10.1111\/ijpp.12302-BIB0050|ijpp12302-cit-0050","unstructured":"Guinea J et\u00a0al Antifungal activity of old and new antifungal agents against 93 clinical isolates of Cryptococcus neoformans var. grubii and var. neoformans: are there differences between the varieties? 2008"},{"key":"10.1111\/ijpp.12302-BIB0051|ijpp12302-cit-0051","doi-asserted-by":"crossref","unstructured":"Curfs-Breuker IM et\u00a0al In vitro activity of isavuconazole (BAL4815) Compared with six other antifungal agents against 180 Cryptococcus neoformans meningitis isolates from The Netherlands 2007","DOI":"10.1016\/S0924-8579(07)71816-2"},{"key":"10.1111\/ijpp.12302-BIB0052|ijpp12302-cit-0052","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1128\/JCM.01420-10","article-title":"Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in\u00a0vitro antifungal susceptibility pattern","volume":"48","author":"Chakrabarti","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1111\/ijpp.12302-BIB0053|ijpp12302-cit-0053","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1128\/AAC.02301-13","article-title":"Isavuconazole therapy protects immunosuppressed mice from mucormycosis","volume":"58","author":"Luo","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0054|ijpp12302-cit-0054","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/JCM.03176-13","article-title":"Isavuconazole treatment of a patient with disseminated mucormycosis","volume":"52","author":"Peixoto","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1111\/ijpp.12302-BIB0055|ijpp12302-cit-0055","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s15010-013-0552-6","article-title":"Successful isavuconazole salvage therapy in a patient with invasive mucormycosis","volume":"42","author":"Ervens","year":"2014","journal-title":"Infection"},{"key":"10.1111\/ijpp.12302-BIB0056|ijpp12302-cit-0056","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11046-010-9324-3","article-title":"Isavuconazole: a comprehensive review of spectrum of activity of a new triazole","volume":"170","author":"Thompson","year":"2010","journal-title":"Mycopathologia"},{"key":"10.1111\/ijpp.12302-BIB0057|ijpp12302-cit-0057","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1128\/AAC.00850-13","article-title":"Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii","volume":"57","author":"Hazirolan","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0058|ijpp12302-cit-0058","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jac\/dkp138","article-title":"In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species","volume":"64","author":"Thompson","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/ijpp.12302-BIB0059|ijpp12302-cit-0059","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1128\/AAC.00685-10","article-title":"In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens","volume":"54","author":"Guinea","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0060|ijpp12302-cit-0060","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/AAC.02157-15","article-title":"Activity of isavuconazole and other azoles against Candida clinical isolates and yeast model systems with known azole resistance mechanisms","volume":"60","author":"Sanglard","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0061|ijpp12302-cit-0061","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/cid\/cit320","article-title":"Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles","volume":"57","author":"Van der Linden","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1111\/ijpp.12302-BIB0062|ijpp12302-cit-0062","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJMc061720","article-title":"Multiple-triazole-resistant aspergillosis","volume":"356","author":"Verweij","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/ijpp.12302-BIB0063|ijpp12302-cit-0063","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.drup.2006.01.001","article-title":"Update on antifungal drug resistance mechanisms of Aspergillus fumigatus","volume":"8","author":"Chamilos","year":"2005","journal-title":"Drug Resist Updat"},{"key":"10.1111\/ijpp.12302-BIB0064|ijpp12302-cit-0064","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"10.1111\/ijpp.12302-BIB0065|ijpp12302-cit-0065","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1371\/journal.pmed.0050219","article-title":"Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism","volume":"5","author":"Snelders","year":"2008","journal-title":"PLoS Med"},{"key":"10.1111\/ijpp.12302-BIB0066|ijpp12302-cit-0066","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1128\/AEM.00231-09","article-title":"Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles","volume":"75","author":"Snelders","year":"2009","journal-title":"Appl Environ Microbiol"},{"key":"10.1111\/ijpp.12302-BIB0067|ijpp12302-cit-0067","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1128\/AAC.00692-10","article-title":"Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain","volume":"54","author":"Mortensen","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0068|ijpp12302-cit-0068","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jac\/dkr443","article-title":"Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR\/L98H mutations in the cyp51A gene in India","volume":"67","author":"Chowdhary","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/ijpp.12302-BIB0069|ijpp12302-cit-0069","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/AAC.50.1.279-285.2006","article-title":"Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers","volume":"50","author":"Schmitt-Hoffmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0070|ijpp12302-cit-0070","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/AAC.50.1.286-293.2006","article-title":"Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers","volume":"50","author":"Schmitt-Hoffmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0071|ijpp12302-cit-0071","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/AAC.04569-14","article-title":"Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study","volume":"59","author":"Cornely","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0072|ijpp12302-cit-0072","unstructured":"Schmitt-Hoffman A et\u00a0al No relevant food effect in man on isavuconazole oral pharmacokinetics preliminary data 2008"},{"key":"10.1111\/ijpp.12302-BIB0073|ijpp12302-cit-0073","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1016\/S0924-8579(07)70828-2","article-title":"Steady-state bioavailability of oral isavuconazole in healthy volunteers","volume":"29","author":"Schmitt-Hoffmann","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/ijpp.12302-BIB0074|ijpp12302-cit-0074","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1128\/AAC.01601-08","article-title":"Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect","volume":"53","author":"Warn","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0075|ijpp12302-cit-0075","unstructured":"Cresemba [package insert] Northbrook, IL Astellas Pharma US, Inc"},{"key":"10.1111\/ijpp.12302-BIB0076|ijpp12302-cit-0076","unstructured":"Schmitt-Hoffman A et\u00a0al Effect of rifampicin on the pharmacokinetics of BAL4815 at steady state after multiple oral doses of BAL8557 (WSA) and rifampicin [P-0319] 2006"},{"key":"10.1111\/ijpp.12302-BIB0077|ijpp12302-cit-0077","unstructured":"Schmitt-Hoffman A et\u00a0al Effect of BAL8557, a water-soluble azole pro-drug (WSA), on the pharmacokinetics of S- and R-warfarin [P-0321] 2006"},{"key":"10.1111\/ijpp.12302-BIB0078|ijpp12302-cit-0078","unstructured":"Schmitt-Hoffman A et\u00a0al Effect of BAL8557, a water-soluble azole pro-drug (WSA), on the pharmacokinetics of ciclosporin [P-0136] 2006"},{"key":"10.1111\/ijpp.12302-BIB0079|ijpp12302-cit-0079","unstructured":"Schmitt-Hoffman A et\u00a0al Effect of BAL8557, a Water-soluble Azole Pro-Drug (WSA) on the pharmacokinetics of Tacrolimus [P-0320] 2006"},{"key":"10.1111\/ijpp.12302-BIB0080|ijpp12302-cit-0080","unstructured":"Yamazaki T et\u00a0al Effect of multiple doses of ketoconazole on the pharmacokinetics of isavuconazole in healthy subjects (abstract no. A-695) 2014"},{"key":"10.1111\/ijpp.12302-BIB0081|ijpp12302-cit-0081","unstructured":"Yamazaki T et\u00a0al Pharmacokinetic (PK) interaction between isavuconazole (ISA) and a fixed-dose combination of lopinavir [LPV] 400\u00a0mg\/ritonavir [RTV] 100\u00a0mg in healthy subjects (abstract no. 722) 2013"},{"key":"10.1111\/ijpp.12302-BIB0082|ijpp12302-cit-0082","unstructured":"Yamazaki T et\u00a0al Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP3A4 substrate atorvastatin in healthy subjects (abstract no. A-449) 2012"},{"key":"10.1111\/ijpp.12302-BIB0083|ijpp12302-cit-0083","first-page":"S39","article-title":"Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP3A4 substrate tacrolimus in healthy subjects","volume":"93","author":"Desai","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/ijpp.12302-BIB0084|ijpp12302-cit-0084","unstructured":"Desai A et\u00a0al Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP2B6 substrate bupropion in healthy subjects (abstract no. A-450) 2013"},{"issue":"Suppl 2","key":"10.1111\/ijpp.12302-BIB0085|ijpp12302-cit-0085","first-page":"227","article-title":"Clinical considerations for coadministration of the novel antifungal isavuconazole with immunosuppressive agents (abstract no. P199)","volume":"26","author":"Townsend","year":"2013","journal-title":"Transplant Int"},{"key":"10.1111\/ijpp.12302-BIB0086|ijpp12302-cit-0086","first-page":"S39","article-title":"Effect of multiple doses of isavuconazole on the pharmacokinetics of cyp3A4 substrate cyclosporine in healthy subjects","volume":"93","author":"Yamazaki","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/ijpp.12302-BIB0087|ijpp12302-cit-0087","unstructured":"Yamazaki T et\u00a0al No effect of pharmacokinetic and pharmacodynamic parameters of warfarin after coadministration with isavuconazole 2013"},{"issue":"1","key":"10.1111\/ijpp.12302-BIB0088|ijpp12302-cit-0088","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14787210.2015.990382","article-title":"Isavuconazole, a broad spectrum triazole for the treatment of systemic fungal diseases","volume":"13","author":"Seyedmousavi","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1111\/ijpp.12302-BIB0089|ijpp12302-cit-0089","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.00319-09","article-title":"Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557","volume":"53","author":"Schmitt-Hoffmann","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0090|ijpp12302-cit-0090","unstructured":"Desai A et\u00a0al Isavuconazole (ISA) population pharmacokinetic modeling from phase 1 and phase 3 clinical trials and target attainment analysis 2014"},{"key":"10.1111\/ijpp.12302-BIB0091|ijpp12302-cit-0091","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1128\/AAC.01364-15","article-title":"Pharmacodynamics of isavuconazole in a dynamic in\u00a0vitro model of invasive pulmonary aspergillosis","volume":"60","author":"Box","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0092|ijpp12302-cit-0092","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1128\/AAC.01355-13","article-title":"Isavuconazole (BAL4815) pharmacodynamic target determination in an in\u00a0vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0093|ijpp12302-cit-0093","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1128\/AAC.01354-13","article-title":"Isavuconazole pharmacodynamic target determination for Candida species in an in\u00a0vivo murine disseminated candidiasis model","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0094|ijpp12302-cit-0094","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/jac\/dkl396","article-title":"Comparative in\u00a0vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus","volume":"58","author":"Warn","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/ijpp.12302-BIB0095|ijpp12302-cit-0095","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jac\/dkn431","article-title":"Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei","volume":"63","author":"Majithiya","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/ijpp.12302-BIB0096|ijpp12302-cit-0096","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1128\/AAC.04586-14","article-title":"A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared to fluconazole in patients with uncomplicated esophageal candidiasis","volume":"59","author":"Viljoen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ijpp.12302-BIB0097|ijpp12302-cit-0097","doi-asserted-by":"crossref","unstructured":"Marty F et\u00a0al An open-label phase 3 study of isavuconazole (VITAL): focus on mucormycosis 2014","DOI":"10.1093\/ofid\/ofu052.532"},{"key":"10.1111\/ijpp.12302-BIB0098|ijpp12302-cit-0098","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by\u00a0Aspergillus\u00a0and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","author":"Maertens","year":"2015","journal-title":"Lancet"},{"key":"10.1111\/ijpp.12302-BIB0099|ijpp12302-cit-0099","unstructured":"ClinicalTrials.gov Safety and isavuconazole (BAL8557) in the treatment of candidemia and other invasive candida infections https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00413218?term=candidiasis&lead=astellas&rank=9"},{"key":"10.1111\/ijpp.12302-BIB0100|ijpp12302-cit-0100","unstructured":"Redbook Online [online database]"},{"key":"10.1111\/ijpp.12302-BIB0101|ijpp12302-cit-0101","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01218-0","article-title":"Isavuconazole: a role for the newest broad-spectrum triazole","author":"Slavin","year":"2015","journal-title":"Lancet"}],"container-title":["International Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijpp.12302","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijpp.12302","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ijpp.12302\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T17:21:22Z","timestamp":1609435282000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1111\/ijpp.12302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,29]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"URL":"https:\/\/doi.org\/10.1111\/ijpp.12302","archive":["Portico"],"relation":{},"ISSN":["0961-7671"],"issn-type":[{"value":"0961-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8,29]]}}}